Pramipexole 2HCl Monohydrate
Molecular Weight(MW): 302.26
Pramipexole 2HCl Monohydrateis a novel non-ergoline dopamine (DA) agonist, used to treat Parkinson's disease.
Purity & Quality Control
Choose Selective Dopamine Receptor Inhibitors
|Description||Pramipexole 2HCl Monohydrateis a novel non-ergoline dopamine (DA) agonist, used to treat Parkinson's disease.|
Pramipexole, a chemically novel dopamine agonist used for the treatment of Parkinson's disease symptoms, possesses antioxidant activity and is neuroprotective toward substantia nigral dopamine neurons in hypoxic-ischemic and methamphetamine models. Pramipexole reduces the levels of oxygen radicals produced by methylpyridinium ion (MPP+) both when incubated with SH-SY5Y cells and when perfused into rat striatum. Pramipexole also exhibits a concentration-dependent inhibition of opening of the mitochondrial transition pore induced by calcium and phosphate or MPP+.  Pramipexole decreases the levels of dopamine metabolites dose dependently, whereas striatal dopamine levels remains unchanged.  Pramipexole acts in both of these models to reduce the elevated dopamine turnover and the associated elevation in hydroxyl radical production secondary to increased MAO activity that could be responsible for oxidative damage to the nigrostriatal neurons.  Pramipexole (4-100 mM) significantly attenuates DA- or L-DOPA-induced cytotoxicity and apoptosis, an action which is not blocked by D3 antagonist U-99194 A or D2 antagonist raclopride. Pramipexole also protects MES 23.5 cells from hydrogen peroxide-induced cytotoxicity in a dose-dependent manner. Pramipexole can effectively inhibit the formation of melanin, an end product resulting from DA or L-DOPA oxidation in cell-free system. 
|In vivo||Pramipexole (0.001-1 mg/kg s.c.) reduces exploratory locomotor activity in mice.  Pramipexole (1 mg/kg, p.o.) is able to significantly reduce the increased DA turnover, but by only 16%. |
|In vitro||Water||60 mg/mL (198.5 mM)|
|DMSO||41 mg/mL (135.64 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03683225||Recruiting||Combination Product: CTC-413||Idiopathic Parkinson Disease||Chase Therapeutics Corporation||April 1 2019||Phase 2|
|NCT03642964||Active not recruiting||Drug: CTC-501||Major Depressive Disorder (MDD)||Chase Therapeutics Corporation||September 10 2018||Phase 2|
|NCT02101138||Active not recruiting||Drug: Dexpramipexole||Hypereosinophilic Syndrome||National Institute of Allergy and Infectious Diseases (NIAID)|Knopp Biosciences|National Institutes of Health Clinical Center (CC)||March 14 2014||Phase 2|
|NCT01733199||Completed||Other: questionnaires||Parkinson''s Disease|Secondary Behavioural Addiction||Nantes University Hospital||October 2012||Phase 4|
|NCT01607034||Completed||Drug: Dexpramipexole||Healthy Volunteers||Knopp Biosciences||June 2012||Phase 1|
|NCT01597310||Completed||Drug: Warfarin|Drug: Dexpramipexole||Healthy Volunteers||Knopp Biosciences||May 2012||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.